Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nalmefene - TaiwanJ Pharmaceuticals

Drug Profile

Nalmefene - TaiwanJ Pharmaceuticals

Alternative Names: JKB-121; Nalmetrene - TaiwanJ Pharmaceuticals

Latest Information Update: 27 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jenken Biosciences
  • Developer Duke University Medical Center
  • Class Antidotes; Antipruritics; Antirheumatics; Drug withdrawal therapies; Hepatoprotectants; Morphinans; Neuroprotectants; Small molecules; Smoking cessation therapies
  • Mechanism of Action Opioid receptor antagonists; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 27 Aug 2019 Discontinued - Phase-II for Non-alcoholic steatohepatitis in USA (PO)
  • 11 Apr 2018 Efficacy and adverse events data from a phase II trial in Non-alcoholic steatohepatitis presented at the International Liver Congress (ILC-2018) (NCT02442687)
  • 29 Sep 2015 TaiwanJ Pharmaceuticals has patents pending for nalmefene in USA and other countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top